Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > TSX promo video ...

<< Previous

Bullboard Posts

Next >>

Comment by Inthepezon Nov 26, 2020 8:07pm

233 Views

Post# 31986311

RE:RE:RE:TSX promo video ...

Deans on mugsy. I see no reason why you can’t factor in Rheumatoid arthritis as well. Both present the same clinically and first line of treat are also the same.

The difference is found out once you start doing blood tests that show signs of autoimmune markers, so they might through immunosuppressant with NSAIDs for RA.
The buyers know this info and have their clinicians turned advisors who inform them of the details lol.

MrMugsy wrote: And Dan recently said that OA is worth $16B and all other indications is worth the same - so another $16B roughly.

He also said they would move quickly into those other indications.

All three drugs take us to $50B+

Then you take is last quote and it looks really exciting ...

“We’re going to initiate a whole new field around what are called the gaseous mediators: nitric oxide, hydrogen sulfide, and carbon monoxide,” Dan Legault, CEO of Antibe Therapeutics, said by phone this month.